14 assets in Fallopian Tube Carcinosarcoma

Therapeutic assets addressing Fallopian Tube Carcinosarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Adriamycin Fallopian Tube Carcinosarcoma	National Cancer Institute (NCI)	P2	B (58)
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine Fallopian Tube Carcinosarcoma	Mayo Clinic	P2	B (58)
Pembrolizumab Fallopian Tube Carcinosarcoma	Mayo Clinic	P2	B (58)
Adsorbed Purified Pertussis Vaccine Fallopian Tube Carcinosarcoma	Mayo Clinic	P2	CCC (53)
Diphtheria Toxoid Fallopian Tube Carcinosarcoma	Mayo Clinic	P2	CCC (53)
Diphtheria Toxoid Adsorbed Fallopian Tube Carcinosarcoma	Mayo Clinic	P2	CCC (53)
Pegcetacoplan Fallopian Tube Carcinosarcoma	Roswell Park Cancer Institute	P2	CCC (53)
Tetanus Toxoid Fallopian Tube Carcinosarcoma	Mayo Clinic	P2	CCC (53)
Pamiparib Fallopian Tube Carcinosarcoma	Sun Yat-sen University	P1/2	CCC (48)
Surufatinib Fallopian Tube Carcinosarcoma	Sun Yat-sen University	P1/2	CCC (48)
Tolinapant Fallopian Tube Carcinosarcoma	National Cancer Institute (NCI)	P1/2	CC (46)
Autologous Muc1-Activated T-Cells Fallopian Tube Carcinosarcoma	Mayo Clinic	P1	CC (43)
Bendamustine Fallopian Tube Carcinosarcoma	Mayo Clinic	P1	CC (43)
Cyclophosphamide Fallopian Tube Carcinosarcoma	Mayo Clinic	P1	CC (43)